Cerebral Blood Flow Measurement of MRI using O-17 labeled water in Normal Subjects and Patients with Chronic Cerebrovascular Disorders
Not Applicable
- Conditions
- normal subjects and patients with chronic cerebrovascular disorders
- Registration Number
- JPRN-UMIN000015981
- Lead Sponsor
- Hokkaido University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
Step1(Normal subjects) (1)metallic implant or claustrophobia (2)chronic disorders (3)CNS, liver, kidney or heart diease (4)acute infection before 30 days (5)drug allergy (6)chronic intake of drugs (> 30 days) (7)other clinical trial (8)willing to have babies (9)person who is contraindicated for this study due to other reasons Step2(Patients) (1)metallic implant or claustrophobia (2)unstable cardiac function (3)severe hepatic or renal disorders (4)acute infection before 30 days (5)drug allergy (6)screening test (7)willing to have babies (8)other clinical trial (9)person who is contraindicated for this study due to other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Signal difference of brain parenchyma between pre- and post-administration of O-17 labeled water and saline
- Secondary Outcome Measures
Name Time Method (1)Efficacy 1)Temporal signal change after administration of O-17 labeled water and saline 2)Correlation between blood flow image and PET in patient group (2)Safety 1) Vital signs (BP, HR, body temperature) 2) Adverse effect